Abstract
Aims: To explore whether the expression of pyroptosis-related lncRNAs makes a difference in the prognosis and antitumor immunity of cutaneous melanoma (CM) patients. Methods: A series of analyses were conducted to establish a prognostic risk model and validate its accuracy. Immune-related analyses were performed to further assess the associations among immune status, tumor microenvironment and the prognostic risk model. Results: Eight pyroptosis-related lncRNAs relevant to prognosis were ascertained and applied to establish the prognostic risk model. The low-risk group had a higher overall survival rate. Conclusion: The established prognostic risk model presents better prediction ability for the prognosis of CM patients and provides new possible therapeutic targets for CM.
To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/epi-2023-0139
Author Contributions
HL Deng and YX Chen designed the study and wrote the manuscript. R An and JC Wang critically revised the manuscript. All authors contributed to the manuscript and approved the submitted version.
Financial & competing interests disclosure
The National Natural Science Foundation of China (grant: 81901977 to R An) provides support for this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Data sharing statement
All transcriptome profiling and corresponding clinical data for CM patients were freely obtained from the TCGA database (https://portal.gdc.cancer.gov/). The 27 genes relevant to the pyroptosis pathway were freely obtained from the GSEA database (www.gsea-msigdb.org/gsea/index.jsp).